

014811-673.119US

9/5/08

PTO/SB/028b (09-05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/584,046		
		Filing Date	September 25, 2006		
		First Named Inventor	Nnochiri N. Ekwuribe		
		Art Unit	1614		
Examiner Name	Phyllis G. Spivack				
Sheet	10	of	10	Attorney Docket Number	014811-673.119

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	72	
	241	M.C. Di PAOLO et al.; Sulfamazine and 5-aminosalicylic acid in long-term treatment of ulcerating colitis: report on tolerance and side-effects, Digest Liver Dis., 2001; pp. 583-589; 33	duplicate duplicate duplicate	
	242	E. K. FIELDS et al.; Diaryl Substituted Maleic Anhydrides; J. Org. Chem.; 1993; pp. 5195-5179; 55; American Chemical Society		
	243	FRIEDRICH NERDEL et al.; Chemical Abstracts, 1981; pp. 443-444; Vol. 55		
1/s	244	Beilstein Search Results, 5522653, 1884		
	245	FRANK D. KING; Bulbosieres, Conformational Restriction, and Pro-drugs - Case History: An Example of a Conformational Restriction Approach; Medicinal Chemistry: Principles and Practice, 1994; pp. 256-225 (pp. 216-217, Table 4); Cambridge, RSC, GB	duplicate	

Examiner Signature	P. Spivack	Date Considered	9/20/08
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.34. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.